Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung.
Article content
'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies.
Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking.
Article content
'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.'
Article content
The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum.
Article content
CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters.
Article content
About CyPath® Lung
Article content
CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.
Article content
About bioAffinity Technologies, Inc.
Article content
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Article content
Forward-Looking Statements
Article content
Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
bioAffinity Technologies
Article content
Article content
Julie Anne Overton
Article content
Article content
Director of Communications
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Enduro Metals Commences 2025 Field Program at the Newmont Lake Project in the Golden Triangle of Northwest British Columbia
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2025) - Enduro Metals Corporation (TSXV: ENDR) ("E nduro", " Enduro Metals" or the" Company") is pleased to provide an update on its 2025 exploration program at the 688 km 2 Newmont Lake project in the Golden Triangle of British Columbia. Highlights: Field crews have mobilised to Newmont Lake and are actively engaged in the phase 1 exploration program. Exploration is currently focused on the Andrei porphyry copper-gold target and initial work at the newly identified Twin target, an early-stage area with limited prior data. The phase 1 program comprises: 2,120 line-kilometers of airborne magnetic surveying (Heli-GT system, 100 metre line spacing) in two blocks. 20 kilometers of ground induced polarization (IP) surveying underway at the Andrei porphyry target; and extensive geological mapping, and rock and soil sampling. Robert Cameron, CEO states: "We are excited to report that our 2025 exploration program at Newmont Lake is well underway. We are particularly encouraged by the scale and quality of the target at Andrei, and the potential to develop a new exploration target at Twin. Our goal this season is to better define these systems and position the company for a focused maiden drill campaign on Andrei, while seeking to increase our understanding of the property's other key targets including Chachi, the Ken Zone, McLymont and the greater Burgundy area. The Newmont Lake project is living up to our expectations as a multi-target, district scale property in a globally significant porphyry belt." ABOUT THE NEWMONT LAKE PROJECT The Newmont Lake Project is one of the largest contiguous claim packages (688 km 2) in the Golden Triangle. It is strategically located near major porphyry copper-gold ("Cu-Au") development projects at Galore Creek (Newmont - Teck) and KSM (Seabridge), as well as high grade past producing gold deposits at Snip and Eskay Creek and new porphyry discoveries including the new North Snip deposit of Seabridge Gold near the southern property boundary. Historic work on the property since the 1980's primarily targeted high-grade gold deposits. Enduro's discovery of the Burgundy Ridge porphyry system in 2021 marked a strategic shift toward copper-gold porphyry exploration. (Figure 1) To view an enhanced version of this graphic, please visit: 2025 Work Program Work by Enduro this year has involved a thorough reassessment of legacy exploration data, enhanced by a newly acquired property wide airborne hyperspectral survey. Existing geophysical data covers approximately 60% of the property with various generations of magnetic surveying, and localised VTEM and DIGHEM electromagnetic survey data and a single ZTEM survey. Geochemical data at varying sample densities covers a similar area and includes SWIR spectral data for rocks samples that complement the regional hyperspectral survey. Historic drilling primarily has been focused at the NW Zone gold deposit (discovered in the 1980's) and the recently discovered Burgundy Ridge alkalic-style porphyry deposit. In 2025, Enduro's new executive management team are prioritizing two main areas - Andrei and Twin - along with developing the Company's geological understanding of its other key targets. The 2025 phase 1 exploration program includes a 2,120 line-kilometer airborne magnetic survey in two blocks utilising a Heli-GT system at a 100-metre line spacing, 20 kilometers of ground induced polarization survey (IP) and extensive geological mapping, rock and soil sampling. (Figure 2) Figure 2: Geology and Targets, Newmont Lake Project To view an enhanced version of this graphic, please visit: Andrei Target The Andrei target is a low-elevation porphyry Cu-Au target located in the northern half of the property. Work in 2022 outlined a 2.5 km trend of porphyry mineralization that was exposed due to recent ice melt at the base of the Andrei glacier. Sample results released by Enduro in 2023 (NR dated April 11) noted highly anomalous copper and gold assay values along the 2.5 km anomaly, with peak results of 4.08 per cent Cu and 57.83 g/t Au. Exposed bedrock comprises potassic altered monzonite with chalcopyrite and bornite in sheeted to stockwork quartz magnetite veinlets. The target extends for over 4.5 kilometres to the southwest through an area with limited bedrock exposure. The current work program includes a high-resolution, low-noise helicopter magnetic survey using a Heli-GT system, a 20 km ground IP survey, and extensive geological mapping and rock sampling, with the objective of defining specific drill targets for a phase 2 drill program, at the end of the 2025 exploration season if conditions and data compilation allow but more probably in 2026. Twin Target The Twin target, located at the southwest corner of the property, is a 7 km extension of the "Bronson Trend" , a 14 kilometre linear alignment of porphyry and porphyry-related deposits that extends from the Quartz Rise deposit northwest to the new North Snip deposit discovered in 2024 by Seabridge Gold. The North Snip deposit is a large gold and copper rich system hosted by potassic altered tuffs that is interpreted by Seabridge to be a zone peripheral to an intrusive hosted porphyry Cu-Au deposit (see Seabridge news releases dated October 9, 2024, January 21, 2025, and June 3, 2025). Work at Twin in 2025 will include airborne magnetic surveying and groundwork including first pass silt sampling, soil sampling and prospecting where feasible. The terrain is rugged and covered by dense mature forest with challenging undergrowth. The airborne magnetic data is expected to be a key tool in target delineation, as Seabridge describes extensive magnetite associated with the potassic alteration at North Snip. Qualified person Mr. Cameron, PGeo, is a qualified person within the context of National Instrument 43-101 and has read and takes responsibility for the technical aspects of this release. About Enduro Metals Enduro Metals is an exploration company focused on its Newmont Lake Project; a total 688 km 2 property located within the heart of British Columbia's Golden Triangle. Building on prior results, Enduro Metals' geological team has outlined multiple deposit environments of interest across the Newmont Lake Project including high-grade epithermal/skarn gold along the McLymont Fault, copper-gold alkalic porphyry mineralization at Burgundy, and newly discovered copper-gold porphyry mineralization at North Toe/Andrei. The Company maintains a broader portfolio of mineral projects across Canada including the advanced Burn porphyry copper and gold project in northern British Columbia. On Behalf of the Board of Directors of Enduro Metals Corporation " Robert Cameron" Chief Executive Officer For further information please contact: Robert Cameron, CEO Tel: +1 (778) 989-1501 Email: cameron@ Forward-Looking Statements This news release contains statements that constitute "forward-looking statements". Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Enduro's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Forward-looking statements in this news release include statements concerning the Parties' expectation with respect to the de-listing of the Commander Shares and the expectation that Commander will apply to cease to be a reporting issuer. Although Enduro believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, forward-looking statements by their nature involve assumptions, known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. .
National Post
24 minutes ago
- National Post
CUPE Ontario Comes Out in Force to Support Striking CUPE 5525 Members at Villa Colombo
Article content TORONTO — Over one hundred CUPE members from around the GTA gathered outside the Villa Charities owned property at the corner of Dufferin and Lawrence Avenue West to bolster the picket line of CUPE 5525. The 25 members of CUPE 5525 have been on strike since the 28 th of March after negotiations to secure their first collective agreement broke down. Villa Colombo hired scab replacement workers and did not engage with the union's bargaining team for weeks. Article content The bolstered picket line blocked all points of entry for vehicle traffic onto the property to disrupt the daily operations of Villa Charities various operations on the site. The bolstered picket line runs from 7:30 to 11:30 AM to have maximum impact on the Villa Charities morning operations. Regular picketing activities will resume in the afternoon. Article content Article content ' We are putting Villa Colombo and Villa Charities on notice that continued disrespect to these striking workers will not be tolerated. CUPE 5525 has the full support of all 230,000 CUPE Ontario members,' said Yolanda McLean, Secretary Treasurer of CUPE Ontario. 'These members are ready to negotiate a fair contract and get back to serving the community they love but today is a reminder that we are also ready and able to ramp up the pressure if needed.' The employer has agreed to a bargaining date on July 29 th, and the two sides are preparing to return to the table to try and find an end to this labour disruption. Key issues on the table include sick day provisions and benefits for part time staff members. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact: Article content Article content Article content Article content
CTV News
24 minutes ago
- CTV News
Hilton lifts 2025 profit forecast on U.S. demand recovery expectations
The Doubletree by Hilton Hotel on King Street in London, Ont. (Daryl Newcombe/CTV News London) Hilton Worldwide lifted its forecast for 2025 profit on expectations of a complete recovery in domestic travel demand in the U.S. after a sharp pullback in March and April. Domestic travel suffered a setback earlier this year after U.S. President Donald Trump's aggressive tariff announcements triggered fears of an economic recession that led consumers to rein in discretionary expenses. Some travel companies recently flagged that travel demand in the U.S. has steadied, but international tourists from Canada and Europe have cut down U.S. visits following Trump's new trade policy. Earlier this month, U.S. legacy carrier Delta Airlines said that while bookings had stabilized, they were at a lower level than the airline had estimated at the start of the year. United Airlines CEO Scott Kirby has made similar remarks, saying that despite demand leveling off, the carrier finished the first half about five percentage points weaker than its original estimate. A slower-than-expected recovery in travel demand also impacted Hilton's second-quarter room revenue in the U.S., which fell 1.5 per cent compared to a year earlier. Shares of the company were down about two per cent in premarket trading. But the company remains hopeful. 'We believe the (U.S.) economy... is set up for better growth over the intermediate term, which should accelerate travel demand,' said Hilton CEO Christopher Nassetta. The McLean, Virginia-based company now expects full-year adjusted profit to be in the range of US$7.83 and $8 per share, compared with its earlier forecast of $7.76 to $7.94. The Waldorf Astoria-parent posted an adjusted profit of $2.20 per share in the second quarter, beating Wall Street estimates of $2.04, according to data compiled by LSEG. Total revenue for the quarter ended June 30 was $3.14 billion, up 6.3 per cent from a year earlier. Analysts, on average, had expected revenue of $3.10 billion. (Reporting by Aishwarya Jain in Bengaluru; Editing by Shinjini Ganguli)
